Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of August 2026, with a report date of August 13, 2026. The document serves as a transaction notification disclosing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2026-08-11 | Ordinary Shares (31 1/2 pence each) | £19.3496 | 126 shares (aggregate) | London Stock Exchange (XLON) |
Note: The aggregate volume of 126 shares is derived from the sum of individual transactions listed in the filing (14 shares each for 8 PDMRs/PCAs, with one exception of 12 shares).
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It reports routine compliance disclosures regarding insider share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only narrative provided is a standard corporate description stating GSK is a global biopharma company uniting science, technology, and talent.
Investor Verification Checklist
- Verify the total number of shares acquired by insiders (126 shares) against the company's broader insider trading reports.
- Confirm the transaction price of £19.3496 aligns with the market price of GSK Ordinary Shares on August 11, 2026.
- Review the specific roles of the eight individuals listed (including the CFO, CEO of ViiV Healthcare, and President of Europe) to assess potential concentration of insider activity.
- Check subsequent filings for any amendments to these initial notifications.